Clinical data acquired over the last decade, especially on non-small cell lung cancer (NSCLC) treatment with small molecular weight EGFR inhibitors, have shown significant influence of EGFR point mutations and in-frame deletions on clinical efficacy23,24. Here, EGFR is linked to non-small cell lung carcinoma.